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Objective: To report on the experience of injections of botulinum toxin A (BTA) in a series of
patients with cerebral palsy of Gross Motor Function Classiﬁcation System (GMFCS) level V.
Methods: This was a retrospective case series study on 33 patients with cerebral palsy of
GMFCS level V who received 89 sessions of BTA application (of which 84 were Botox® and
ﬁve  were other presentations), in which the basic aim was to look for adverse effects.
Results: The mean number of application sessions per patient was three, and the mean age
at  the time of each injection was  4 + 6 years (range: 1.6–13 years). The muscles that most
frequently  received injections were the gastrocnemius, hamstrings, hip adductors, biceps
brachii  and ﬁnger ﬂexors. The mean total dose was 193 U and the mean dose per weight
was  12.5 U/kg. Only one patient received anesthesia for the injections and no sedation was
used  in any case. No local or systemic adverse effects were observed within the minimum
follow-up  of one month.
Conclusion:  The absence of adverse effects in our series was probably related to the use of low
doses  and absence of sedation or anesthesia. According to our data, BTA can be safely used
for  patients with cerebral palsy of GMFCS level V, using low doses and preferably without
sedation  or anesthesia.
© 2014 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda.    
Tratamento  focal  da  espasticidade  com  toxina  botulínica  A  na  paralisia
cerebral  GMFCS  nível  V  –  Avaliac¸ão  de  efeitos  adversos
r  e  s  u  m  o
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aralisia cerebral
spasticidade muscular
oxinas  botulínicas
Objetivo: relatar a experiência da aplicac¸ão  de toxina botulínica A (TBA) em uma  série de
pacientes  com paralisia cerebral (PC) GMFCS nível V.
Métodos: estudo retrospectivo de série de casos, 33 pacientes com PC GMFCS nível V que
receberam  89 sessões para aplicac¸ão  de TBA (84 Botox® e cinco outras apresentac¸ões),  em
busca  basicamente de efeitos adversos.
 Please cite this article as: Tedesco AP, Martins JS, Nicolini-Panisson RD. Tratamento focal da espasticidade com toxina botulínica A na
aralisia cerebral GMFCS nível V – Avaliac¸ão  de efeitos adversos. Rev Bras Ortop. 2014;49:359–363.
 Work performed in the Neuro-Orthopedics Institute, Caxias do Sul, RS, Brazil.
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Resultados: o número médio de sessões para aplicac¸ão  por paciente foi três e a idade média
em cada injec¸ão  foi 4 + 6 anos (1,6–13 anos). Os músculos mais frequentemente injeta-
dos foram gastrocnêmios, isquiotibiais, adutores do quadril, bíceps braquial e ﬂexores dos
dedos. A dose média total foi 193 U e a dose média por peso foi 12,5 U/k. Somente um paciente
recebeu anestesia para as injec¸ões  e sedac¸ão  não foi usada em qualquer caso. Não foram
observados efeitos adversos locais ou sistêmicos dentro de seguimento mínimo de um mês.
Conclusão: a ausência de efeitos adversos em nossa série está provavelmente relacionada
ao uso de doses baixas e ao não emprego de sedac¸ão  ou anestesia. De acordo com nossos
dados, a TBA pode ser usada de forma segura em pacientes com PC GMFCS nível V, em doses
baixas e preferencialmente sem sedac¸ão  ou anestesia.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por ElsevierIntroduction
Botulinum toxin type A (BTA) has been used for more
than two decades for treating spasticity in cerebral palsy
cases,  especially in the age group from two to eight years
and  in cases of focal dynamic deformities, with the main
aim  of postponing surgical procedures through controlling
the  deformity. Many  studies have shown that if the total
dose,  dose per unit weight and application technique are
respected,  BTA is safe to use and adverse effects are practically
absent.1
However, some rare cases of serious adverse effects have
been  reported over the last few years, relating to patients
with  Gross Motor Function Classiﬁcation System (GMFCS) level
V.  These are patients with severe impairment who cannot
walk,  present little or no control over their head position and
often  have respiratory dysfunctions of various degrees. The
reports  have concluded that there is a relationship with the
preexisting  respiratory dysfunctions, such as pseudobulbar
palsy, which suggests that other types of therapy should be
used  for treating these patients.2–6 Despite the generalized
pattern of spasticity, BTA may  be indicated for patients with
GMFCS  level V in an attempt to improve posture and posi-
tioning,  alleviate discomfort and facilitate care and orthosis
use.6
In our experience, BTA has been shown to be com-
pletely safe, independent of the GMFCS level. The aim of
this  study was  to report on our experience of applying BTA
to  a series of patients with cerebral palsy of GMFCS level
V.
Materials  and  methods
Between 2000 and 2010, 188 patients with cerebral palsy
underwent 412 sessions of BTA application, performed by
the  ﬁrst author. Of these, 33 patients were at GMFCS level
V.  They received BTA in 89 sessions and were  the target of
the  analysis in this study. A free and informed consent state-
ment  was  obtained from all the patients, for application of
the  medication and for use of the data relating to the treat-
ment,  while maintaining conﬁdentiality of identity. The study
was  approved by the Circle Research Ethics Committee (Serra
Gaúcha  Foundation).Editora  Ltda. 
Results
Among the patients, 25 were  male and eight were  female.
Their  mean age at the time of the applications was  four years
and  six months (minimum age of one year and six months
and  maximum of 13 years). Around 50% of the patients pre-
sented  a clinical report of difﬁculties in swallowing and three
were  using gastrostomy as the sole means of feeding. Several
patients  had histories of pulmonary complications and 12 had
already  needed hospital treatment. At the time of the injec-
tions,  all the patients were in a good state of health, without
using  antibiotics. The application sessions took place without
sedation  or anesthesia, except in one case in which anesthesia
was  administered by means of a mask.
The patients came for the sessions after orthopedic assess-
ment,  in which planning for which muscles the BTA would
be  applied to was  conducted, along with calculation of the
total  dosage and the dosage per application point. The total
dose  and dose per unit weight, the muscles injected and the
dose  per application point were recorded. The results and any
occurrences  of adverse effects were noted during the follow-
up.
Botox® was  the presentation of BTA used in 84 injections,
and other presentations were used in ﬁve cases: two applica-
tions  of Dysport® and three of Prosigne®. The mean total dose
of  Botox® was  193 U, ranging from 100 to 300 U. The total dose
of  Dysport® was 500 U in the two applications, with a mean
dose  of 45 U/kg in one application and 50 U/kg in the other.
The  total dose of Prosigne® was  200 U in the three applica-
tions and the doses per unit weight were 14, 12.5 and 16 U/kg.
In  62 injections, the mean dose was 12.5 U/kg for the Botox®
presentation, with a range from 6 to 22 U/kg; in 27 injections,
the  dose per unit weight was  not identiﬁed in reviewing the
medical  ﬁle.
The  mean number of sessions per patient was  2.7; 13 (40%)
had  only one session and eight (24%) had two. Two patients
(6%)  had nine sessions. The minimum interval between the
applications  was  six months.
The  muscles most frequently injected were  the gastroc-
nemius (61 injections), hamstrings (54), hip adductors (30),
biceps  brachii (28) and long ﬂexors of the ﬁngers (26). The
other  muscles injected were the wrist ﬂexors, thumb adduc-
Este é um artigo Open Access sob a licença de CC BY-NC-NDtor  and pronator teres. The mean number of muscle groups
injected  per session was  three. Three muscle groups were
injected  in 31 sessions, two muscle groups in 23 and one
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uscle group in 11. In almost all the sessions, the application
as  bilateral.
iscussion
TA makes an unquestionable contribution toward man-
gement  of spasticity. The great majority of studies in the
iterature  have demonstrated low rates of complications
nd adverse effects. A review in 2009 on studies conducted
etween 1990 and 2008 (20 studies in the meta-analysis, with
82  participants) showed that there were  only 35 adverse
vents, which were  all mild, including respiratory infections,
ronchitis, pharyngitis, asthma, muscle weakness, urinary
ncontinence, falls, convulsions and nonspeciﬁc pain. It con-
luded  that BTA was  safe to use in cerebral palsy cases.1
oté et al.7 reviewed the report system of the Food and Drug
dministration (FDA), in the United States, covering the years
989–2003,  searching for adverse effects from BTA (Botox®)
or  esthetic or cosmetic use. They identiﬁed 1437 reports of
dverse  effects: 1031 from cosmetic use and 406 from ther-
peutic  use. In both types of indication, the majority of the
atients  who had adverse effects were women  with a mean
ge  of 50 years. Among the 406 cases of adverse events from
herapeutic  use, 217 were  classiﬁed as serious, including 28
eaths  (due to respiratory arrest, myocardial infarction, stroke,
ulmonary  embolism and pneumonia, including aspiration
neumonia), and 26 of them had underlying diseases. The
ean  age among the patients who died was  44 years. It is
mportant  to emphasize that this study did not cite the diag-
oses  of the patients treated with BTA and did not make any
ge  distinction for patients under the age of 20 years. There-
ore,  no parallel with our data can be traced out.7
Patients with GMFCS level V present spasticity with defor-
ities  at multiple levels that often require a broader approach,
ith  use of oral or intrathecal medications. However, there are
ndications for focal management of spasticity, with a view to
mprovement of the positioning and facilitation of the use of
rthoses  and daily care.
Recently, reports of cases in which severe complications,
ncluding death, occurring through administration of BTA
n  cerebral palsy cases were  published, with linkage to
reater  severity of functional impairment (GMFCS level V).
he  adverse effects most frequently reported have been
espiratory difﬁculties and urinary incontinence, which can
lmost  always be explained by local and/or hematogenic dis-
emination  of the drug and autonomic denervation through
etrograde migration. Adverse effects of generalized weakness
rom  BTA in treatments for spasticity and dystonia have also
een  described and likewise explained in terms of systemic
issemination with pre-synaptic inhibition. One study in
hich  a muscle biopsy was  performed in a muscle distant
rom  the application site demonstrated denervation. Retro-
rade  axonal transport therefore cannot be ruled out.2,3,8–10
linical conditions of botulism have been described after
dministration of BTA, almost always related to excessively
igh  doses, such as 40 U/kg. Other authors reported a similar
ase,  in a patient with GMFCS level, from the description, who
as  using gastrostomy. No use of anesthesia or sedation was
ited.  The patient’s condition of severe respiratory difﬁculty,;4 9(4):359–363  361
ptosis,  fecal impaction, urinary retention and fever was
interpreted as iatrogenic botulism.11,12
In the literature, there seems to be a relationship between
high  total doses and occurrences of adverse effects, not nec-
essarily  in cases with GMFCS level V. In 2001, Bakheit et al.13
examined the data from 758 patients (94% with spastic cere-
bral  palsy and 29% quadriplegic) who had received 1594
treatments with BTA (Dysport®). Sedation or anesthesia was
used  in 31% of the cases. The patients were not classiﬁed using
the  GMFCS, and it was  only stated that 13% of them could
only  walk at home, while the others were able to walk in the
community. The mean dose used was 22.9 U/kg and the max-
imum  total dose was 2360 U. Adverse effects were  found in
7%,  among which the most frequent were localized muscle
weakness (which was explained as resulting from local dis-
semination  of the drug) and urinary incontinence (explained
as  autonomic dysfunction). These were mainly correlated with
high  total doses (greater than 1000 U), but there was  no corre-
lation  with the functional level or the dosage per unit weight.
Weakness in distant muscles occurred in a small percentage
of  cases and, according to these authors, may  have been due to
chemical denervation. They concluded that BTA was  safe for
treating  spasticity in children when used at doses of less than
1000  U (for Dysport®), and that lower doses could be used with-
out  impairing attainment of the desired results.13 It needs to
be  taken into consideration that there is no precise correlation
between the doses of Botox® and Dysport®.
The relationship between complications and GMFCS level
V  was  demonstrated by Howell et al. in 2007.5 They published
a  case report on an adverse reaction to application of 400 U of
BTA  (Botox®), i.e. 20–25 U/kg, in a nine-year-old patient who
presented  quadriplegic spastic cerebral palsy of GMFCS level
V  and was  treated under general anesthetic. This patient was
using  gastrostomy. He developed respiratory difﬁculty after
the  ﬁrst injection, which was  repeated after the second, third
and  fourth injections, and on the last three occasions had to
be  admitted to hospital. The authors explained the respiratory
complications on the basis of the presence of pseudobulbar
palsy, which alters laryngeal and pharyngeal function. These
are  under neural control, mediated by cholinergic terminals,
and  are therefore subject to blockage through the action of
BTA.  The authors stated that BTA might spread beyond the
muscle  motor points in certain circumstances and speculated
that  it would not be possible to rule out allergic reactions as
a  cause of the adverse effects that occurred. They concluded
that  patients with GMFCS level V, who often present risk fac-
tors  such as pseudobulbar palsy, respiratory difﬁculties and
swallowing  problems, should receive much  lower doses of
BTA,  i.e. between 4 and 6 U/kg.5
In 2010, Naidu et al.14 published the results from 1980 BTA
in  lower limbs, under anesthesia applied through a mask,
among  250 patients of GMFCS level V.14 There was  a low
complication rate in the general sample (1% with inconti-
nence  and 1.3% with respiratory abnormalities), and these
complications were  correlated with use of high doses of BTA.
The  mean dose used was  252 U in total (13.4 U/kg) and the
mean  number of muscle groups was three. Among these, the
gastrocnemius  and hamstrings were the muscles most fre-
quently  injected. There was  one death, which was  related to
respiratory  complications resulting from epilepsy. The risk of
p . 2 0 362  r e v b r a s o r t o 
respiratory complications was  correlated with GMFCS level V
and to the presence of pseudobulbar palsy, histories of respi-
ratory  diseases and use of inhaled anesthesia. Among the 71
patients  in the general sample who showed adverse effects, 24
received  a second dose of BTA and two developed new adverse
effects.  The authors recommended that patients with GMFCS
level  V should not be treated with BTA, while those with level
IV  should receive a maximum dose of 18 U/kg. In our study,
reapplications were made, without any appearance of adverse
effects,  even in the patients who  presented some degree of
respiratory  dysfunction or swallowing difﬁculty and gastros-
tomy.  It should be noted that in our sample, no anesthesia or
sedation was  used and the doses used were  smaller.
A  consensus published in 2010 advised that the total dose
and  the dose per unit weight should be calculated more care-
fully  in patients with GMFCS level V and in those presenting
respiratory dysfunctions and/or dysphagia, and that an inter-
val  of not less than six months should be given between
applications.6
On the other hand, even with higher doses, in 2010 Unlu
et  al.10 published the results from administration of BTA
under  sedation (midazolam) among 71 patients, of whom 33%
presented GMFCS level V. There was  no mention of any compli-
cations  or adverse effects, with doses of 15–20 U/kg of Botox®
or 30 U/kg of Dysport®, and the maximum doses were respec-
tively  300 U and 500 U. The absence of complications may  have
been  related to nonuse of anesthesia.
However, this relationship with nonuse of anesthesia could
not  be proven in another study, in which adverse effects
were  observed in 76 patients with GMFCS level V who had
received  BTA under sedation or anesthesia through a mask.
Among  these patients, 72% presented histories of dysphagia
and  almost half were  using gastrostomy. The authors mon-
itored  the appearance of sentinel events, i.e. worsening of
dysphagia,  generalized weakness and infectious events of the
lower  airways. Adverse events occurred in more  than 20% of
the  total number of cases. Among level V patients, three pre-
sented  worsening of dysphagia and four had an infectious
event of the lower airways; all of them had histories of dyspha-
gia.  There were  no deaths. None of the patients who showed
sentinel  events had received BTA under general anesthesia.9
Most reports that have described adverse events from BTA
have  indicated that dissemination to locations far from the
application  sites, such as the swallowing and/or respiratory
muscles, as possible causes of complications. However, it
is  unclear in the literature whether serious complications
such as respiratory dysfunction and death might be related
to  underlying conditions that were  now in a threshold state,
given  that these patients generally presented adverse effects
that  were  directly related to BTA. This population of patients is
frequently dependent on gastrostomy for feeding, since they
present  aspiration of foods to the airways, which has often
been  documented. Thus, these are situations in which deep
sedation  or anesthesia could be incriminated as the cause of
signiﬁcant  lack of protection of the airways, thereby favoring
aspiration  and retention of secretions. Such conditions in
14 15these  patients could be lethal. Olney et al. used electroneu-
romyographic to investigate distant neuromuscular effects (in
the biceps brachii) after application of 280 U of BTA in the neck
muscles.  They did not ﬁnd any electrophysiological signals of1 4;4 9(4):359–363
pre-synaptic blockage and concluded that higher dose could
be  used if necessary. Thus, it could be presumed that only
incontinence could be attributed solely to use of BTA, given
that  respiratory complications are very common in these
patients,  even without any intervention, and it could also
be  asked whether the sedation and/or anesthesia procedure
alone  might be incriminated. They suggested that options
other  than anesthesia using a mask and adaptation of doses
would  be desirable among patients with GMFCS levels IV and
V.  Occurrences of urinary and/or fecal incontinence are often
difﬁcult  to register among patients with GMFCS level V, who
generally  do not have sphincter control.
In our study, we  did not have any adverse effects, possibly
because the doses used were low: a mean of 193 U (12.5 U/kg).
In  only 15 applications did the patients receive more  than
15  U/kg, and in only two cases, more  than 20 U/kg; and no seda-
tion  or anesthesia was  used. This mean dose was  lower than
the  mean doses used in studies in which complications were
shown.5,13,14 It seems that it was impossible to make any corre-
lation  with preexisting respiratory pathological conditions in
our sample, given that we  did not have any complications. This
occurred even though around 50% of the patients had clinical
reports  of difﬁculties with swallowing and aspiration (three
patients  were using gastrostomy as the sole route for feeding),
several  patients had histories of pulmonary complications and
12  required hospital treatment.
The literature shows that adverse effects from using BTA
for  treating spasticity in cerebral palsy cases are rare. Such
effects  include generalized muscle weakness, urinary incon-
tinence,  botulism and respiratory complications, and they
correlate  mainly with the respiratory complications at GMFCS
level  V. It is important to emphasize that the respiratory
adverse effects occurred in patients who received high doses,
already  had underlying respiratory dysfunctions and under-
went  sedation or anesthesia for the applications. The adverse
effects  might be related to systemic dissemination or auto-
nomic  dysfunction due to retrograde pre-synaptic inhibition.
Studies  have recommended that these patients, who often
present  risk factors such as underlying respiratory and swal-
lowing  difﬁculties and have not received BTA, should be
treated  with low doses without sedation or anesthesia, since
there  is a likely correlation between these factors and the com-
plications.  In our study, in which the patients were  treated
with  intermediate doses, without sedation or anesthesia,
there were  no complications.
Conclusion
From our ﬁndings, BTA can be used for focal treatment of spas-
ticity  in patients with cerebral palsy of GMFCS level V, provided
that  low doses are used, without using sedation or anesthesia.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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